- Home
- CGEN vs MCN Comparison
CGEN vs MCN Comparison
Compare CGEN & MCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- MCN
- Stock Information
- Founded
- CGEN 1993
- MCN 2004
- Country
- CGEN Israel
- MCN Canada
- Employees
- CGEN N/A
- MCN N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- MCN
- Sector
- CGEN Health Care
- MCN
- Exchange
- CGEN Nasdaq
- MCN Nasdaq
- Market Cap
- CGEN 125.3M
- MCN 125.6M
- IPO Year
- CGEN 2000
- MCN N/A
- Fundamental
- Price
- CGEN $1.58
- MCN $5.92
- Analyst Decision
- CGEN
- MCN
- Analyst Count
- CGEN 0
- MCN 0
- Target Price
- CGEN N/A
- MCN N/A
- AVG Volume (30 Days)
- CGEN 522.7K
- MCN 52.9K
- Earning Date
- CGEN 11-10-2025
- MCN 01-01-0001
- Dividend Yield
- CGEN N/A
- MCN 9.96%
- EPS Growth
- CGEN N/A
- MCN N/A
- EPS
- CGEN N/A
- MCN N/A
- Revenue
- CGEN $22,144,000.00
- MCN N/A
- Revenue This Year
- CGEN N/A
- MCN N/A
- Revenue Next Year
- CGEN $208.08
- MCN N/A
- P/E Ratio
- CGEN N/A
- MCN N/A
- Revenue Growth
- CGEN N/A
- MCN N/A
- 52 Week Low
- CGEN $1.13
- MCN $6.69
- 52 Week High
- CGEN $2.66
- MCN $8.60
- Technical
- Relative Strength Index (RSI)
- CGEN 44.43
- MCN 33.48
- Support Level
- CGEN $1.61
- MCN $5.96
- Resistance Level
- CGEN $1.80
- MCN $6.19
- Average True Range (ATR)
- CGEN 0.11
- MCN 0.07
- MACD
- CGEN -0.03
- MCN -0.01
- Stochastic Oscillator
- CGEN 19.35
- MCN 6.86
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About MCN Madison Covered Call & Equity Strategy Fund
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.